NCT06156644

Brief Summary

In this first-in-human clinical trial a novel generator (INTELLAPULSE), designed and built by Stockert, which supports highly flexible PFA protocols as well as RF interventions will be used. For 12 months and follow-up for 12 months, after a 3-months blanking period 50 consecutive paroxysmal AF patients, eligible for catheter ablation, will be enrolled.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at below P25 for not_applicable atrial-fibrillation

Timeline
6mo left

Started Jul 2025

Shorter than P25 for not_applicable atrial-fibrillation

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress63%
Jul 2025Dec 2026

First Submitted

Initial submission to the registry

November 13, 2023

Completed
22 days until next milestone

First Posted

Study publicly available on registry

December 5, 2023

Completed
1.6 years until next milestone

Study Start

First participant enrolled

July 1, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Expected
Last Updated

January 3, 2024

Status Verified

December 1, 2023

Enrollment Period

5 months

First QC Date

November 13, 2023

Last Update Submit

December 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • number of death

    Primary endpoints focusing of the safety of the strategy

    12 month

Study Arms (1)

PFA strategy

OTHER

PFA will be performed based on a specific protocol

Device: PFA

Interventions

PFADEVICE

Ablation to treat trail fibrillation

PFA strategy

Eligibility Criteria

Age18 Years+
Sexall(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • new onset atrial fibrillation

You may not qualify if:

  • age \<18 years
  • previous left atrial ablation
  • lack or withdrawal of written informed consent
  • unable to receive ablation therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Atrial Fibrillation

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: Single Arm
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof

Study Record Dates

First Submitted

November 13, 2023

First Posted

December 5, 2023

Study Start

July 1, 2025

Primary Completion

December 1, 2025

Study Completion (Estimated)

December 1, 2026

Last Updated

January 3, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share